Direct Oral Anticoagulant Use: A Practical Guide to Common
Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long-standing standard of care in anticoagulation, vitamin K antagonist. DOACs are indicated for prevention and treatment of several cardiovascular conditions.
Direct Oral Anticoagulant Use: A Practical Guide to Common
Direct oral anticoagulants (DOACs)—dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), and betrixaban (Bevyxxa) are anticoagulation pharmacotherapy used for the prevention of thrombosis in several cardiovascular contexts. 1 DOACs are categorized into 2 main classes: oral direct factor Xa inhibitors (ie,
Direct Oral Anticoagulant Use: A Practical Guide to Common
irect oral anticoagulants (DOACs)—dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), and betrixaban (Bevyxxa) are anticoagulation pharmacotherapy used for the preven- tion of thrombosis in several cardiovascular contexts.1
Frontiers | Direct Oral Anticoagulants: From Randomized
Direct oral anticoagulants (DOACs) are a more manageable alternative than vitamin K antagonists (VKAs) to prevent stroke in patients with nonvalvular atrial fibrillation and to prevent and treat venous thromboembolism.
DOACs vs. Warfarin in Patients With Valvular Atrial
DOACs, compared with warfarin, were associated with lower risks for ischemic stroke or systemic embolism and major bleeding events in patients with valvular AF. These results suggest that patients with a broad definition of valvular heart disease may be able to safely use DOACs.
- What are direct oral anticoagulants?
- Direct oral anticoagulants (DOAC s) have quickly become attractive alternatives to the long‐standing standard of care in anticoagulation, vitamin K antagonist. DOAC s are indicated for prevention and treatment of several cardiovascular conditions.
- Are direct oral anticoagulants better than vitamin-K-antagonists for venous thromboembolism?
- 1 Institut für Hausarztmedizin Universitätsspital Zürich (IHAMZ), Zürich. Due to their advantageous benefit-risk-profile, direct oral anticoagulants (DOACs) are preferred over vitamin-K-antagonists for stroke prevention in atrial fibrillation as well as therapy and secondary prevention of venous thromboembolism.
- Are direct oral anticoagulants a good alternative to vitamin K antagonist?
- ABSTRACT: Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long- standing standard of care in anticoagulation, vitamin K antagonist. DOACs are indicated for prevention and treatment of several cardiovascular con-ditions.
- Can a parenteral anticoagulant be transitioned from a VKA to a DOAC?
- Parenteral anticoagulant: LMWH or UFH. Transitioning between VKA and DOAC and vice versa requires additional explanation that takes into account the INR measurement. When transitioning from a VKA to a DOAC, the half‐life of the VKA compound is imperative to guide therapy.
- Can a patient transition from anticoagulants to DOAC therapy?
- As with any high‐risk medication such as anticoagulants, clinical situations may arise that require transitioning to or off of DOAC therapy. Two common transition scenarios include (1) switching between anticoagulants and (2) periprocedural management.
- What is a DOAC guideline for venous thromboembolism?
- This guideline provides information on the practical use of DOACs, their advantages and disadvantages and limitations. It is based on recommendations from international guidelines (ESC, EHRA, DGA) and adapts them for the general practitioner setting in Switzerland. Keywords: DOAKs; atrial fibrillation; venous thromboembolism.
